logo
Plus   Neg
Share
Email

Sandoz's Data Shows Effectiveness Of Erelzi In Rheumatic Disease Treatment

Sandoz, a Novartis division, presented real-world data showing effectiveness of Erelzi in rheumatic disease treatment.

Patients with rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and ankylosing spondylitis (AS) were included in the COMPACT study, the company said.

In addition to the COMPACT analysis, Sandoz presented results from a US economic model. Investigators evaluated the economic impact of switching patients from a reference etanercept to a biosimilar in patients with rheumatic diseases in the US, taking into consideration the upfront costs when implementing a formulary change.

Sandoz said the results demonstrated that despite the early, administrative costs associated with managing the formulary process, substantial cost savings can be realized by integrated delivery networks (IDNs) when transitioning patients to the biosimilar.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT
>